Risk factors for progression of chronic kidney disease in the eppic trials and the effect of AST-120

Clinical and Experimental Nephrology

Volumn 22, Issue 2, 2018, Pages 299-308

  Schulman, Gerald ^a   Berl, Tomas ^b   Beck, Gerald J ^c   Remuzzi, Giuseppe ^d,e,f   Ritz, Eberhard ^g   Shimizu, Miho ^h   Kikuchi, Mami ⁱ   Shobu, Yuko ⁱ  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d Azienda Ospedaliera Papa Giovanni XXIII   (Italy)

^e MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g UNIVERSITY OF HEIDELBERG   (Germany)

^h MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

ⁱ KUREHA CORPORATION   (Japan)

Author keywords

AST 120; CKD; CKD progression; Clinical trial; Spherical carbon adsorbent; Uremic toxins

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AST 120; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; BIOLOGICAL MARKER; CARBON; OXIDE;

ADULT; ARTICLE; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEMATURIA; HIGH RISK PATIENT; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MICROCAPSULE; MIDDLE AGED; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; KIDNEY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PROTEINURIA; TIME FACTOR; TREATMENT OUTCOME; URINE;

ADULT; AGED; BIOMARKERS; CARBON; CREATININE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HEMATURIA; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OXIDES; PROTEINURIA; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 85025604459     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-017-1447-0     Document Type: Article

References (19)

1. United States Renal Data System. 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD. 2015. http://www.usrds.org/2015/view/v2_13.aspx. Accessed 25 Mar 2016
2. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003;108:2154–69.
3. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. CKD Prognosis Consortium. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518–31.
4. Japanese Nephrology Society. Special issue: Clinical practice guidebook for diagnosis and treatment of chronic kidney disease 2012. Nihon Jinzo Gakkai Shi. 2012;54:1034–191 (article in Japanese).
5. Schulman G, Vanholder R, Niwa T. AST-120 for the management of progression of chronic kidney disease. Int J Nephrol Renovasc Dis. 2014;7:49–56.
6. Schulman G, Berl T, Beck GJ, Remuzzi G, Ritz E, Arita K, et al. Randomized placebo-controlled EPPIC trials of AST-120 in CKD. J Am Soc Nephrol. 2015;26:1732–46.
7. Levey AS, Greene T, Kusek JW, Beck GJ. MDRD Study Group, a simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol (Abstr). 2000;11:155A.
8. Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL Study. Kidney Int. 2003;63:1499–507.
9. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuremia and the risk of developing end-stage renal disease. Kidney Int. 2003;63:1468–74.
10. Yamagata K, Takahashi H, Tomida C, Yamagata Y, Koyama A. Prognosis of asymptomatic hematuria and/or proteinuria in men. High prevalence of IgA nephropathy among proteinuric patients found in mass screening. Nephron. 2002;91:34–42.
11. Vivante A, Afek A, Frenkel-Nir Y, Tzur D, Farfel A, Golan E, et al. Persistent asymptomatic isolated microscopic hematuria in Israeli adolescents and young adults and risk for end-stage renal disease. JAMA. 2011;306:729–36.
12. You-Hsien Lin H, Yen CY, Lim LM, Hwang DY, Tsai JC, Hwang SJ, et al. Microscopic haematuria and clinical outcomes in patients with stage 3–5 nondiabetic chronic kidney disease. Sci Rep. 2015;5:15242.
13. Yuste C, Rubio-Navarro A, Barraca D, Aragoncillo I, Vega A, Abad S, et al. Haematuria increases progression of advanced proteinuric kidney disease. PLoS One. 2015;10(5):e0128575.
14. O’Neill WM Jr, Wallin JD, Walker PD. Hematuria and red cell casts in typical diabetic nephropathy. Am J Med. 1983;74:389–95.
15. Morita S, Fukuhara S, Akizawa T, Asano Y, Kurokawa K. Study design and methods for a clinical trial of an oral carbonaceous adsorbent used to prevent the progression of chronic kidney disease (CAP-KD). Clin Exp Nephrol. 2005;9:219–27.
16. Akizawa T, Asano Y, Morita S, Wakita T, Onishi Y, Fukuhara S, et al. CAP-KD Study Group. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial. Am J Kidney Dis. 2009;54:459–67.
17. Cha RH, Kang SW, Park CW, Cha DR, Na KY, Kim SG, et al. A randomized, controlled trial of oral intestinal sorbent AST-120 on renal function deterioration in patients with advanced renal dysfunction. Clin J Am Soc Nephrol. 2016;11(4):559–67.
18. Cha RH, Kang SW, Park CW, Cha DR, Na KY, Kim SG, et al. Sustained uremic toxin control improves renal and cardiovascular outcomes in patients with advanced renal dysfunction: post hoc analysis of the Kremezin Study against renal disease progression in Korea. Kidney Res Clin Pract. 2017;36(1):68–78.
19. Ito S, Yoshida M. Protein-bound uremic toxins: new culprits of cardiovascular events in chronic kidney disease patients. Toxins (Basel). 2014;6(2):665–78.